Section Arrow
Quote
SRRK.NASDAQ
- Scholar Rock Holding Corp
Quotes are at least 15-min delayed:2026/06/01 06:57 EDT
Pre Market
Last
 51.75
+2.45 (+4.97%)
Bid
45.85
Ask
51.79
High 51.75 
Low 49.3 
Volume 5 
Regular Hours (Closed)
Last
 49.3
-0.52 (-1.04%)
Day High 
50.18 
Prev. Close
49.82 
1-M High
52.185 
Volume 
2.14M 
Bid
45.85
Ask
51.79
Day Low
48.94 
Open
50.04 
1-M Low
45 
Market Cap 
5.97B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 49.18 
20-SMA 48.4 
50-SMA 47.61 
52-W High 52.185 
52-W Low 27.07 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.45/-2.20
Enterprise Value
6.07B
Balance Sheet
Book Value Per Share
2.30
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.1172-0.0468-28.54%-- 
Pre Market 0.0812 -0.036 -30.72%
REPLReplimune Group8.69+4.01+85.68%-- 
Pre Market 9.765 +1.075 +12.37%
CDTCDT Equity Inc.1.04+0.0899+9.46%-- 
Pre Market 0.9403 -0.0997 -9.59%
CMNDClearmind Medicine Inc.3.58+1.13+46.12%-- 
Pre Market 2.554 -1.026 -28.66%
OTLKOutlook Therapeutics0.73-0.01-1.35%-- 
Pre Market 0.695 -0.035 -4.79%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.